Atrial Fibrillation (AF)CCT-EAT-AF-NANCT07320261
Cardiac CT Evaluation of EAT in AF vs. Non-AF Subjects
An observational study of Atrial Fibrillation (AF) and CT, run by xiaoya wang.
Trial summary
The goal of this cross-sectional study is to explore the relationship between atrial structural characteristics (such as epicardial adipose tissue infiltration and atrial size) and atrial fibrillation (AF), as well as the differences in these characteristics among different AF subtypes. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Atrial Fibrillation (AF), CT
- How many people
- 600 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2026to Aug 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study population consists of adult patients aged 18 years or older who undergo coronary CTA or left atrial CTA examination at The Second Affiliated Hospital of Zhejiang University School of Medicine. Participants will be categorized into three cohorts according to their confirmed cardiac rhythm status: sinus rhythm, paroxysmal atrial fibrillation, or persistent atrial fibrillation. All enrolled individuals must be willing to provide clinical baseline data and allow access to their CTA examination results, and be able to understand and cooperate with the study's data collection process. Patients under 18 years of age, those with incomplete clinical data or unreadable CTA images, and those who refuse to participate or cannot cooperate will be excluded from the study. The total planned sample size is 600-900 participants, with 200-300 participants in each cohort.
Who may be able to join
- Patients who undergo coronary CTA or left atrial CTA examination at The Second Affiliated Hospital of Zhejiang University School of Medicine;
- Aged 18 years or older
- Cardiac rhythm status is confirmed as sinus rhythm, paroxysmal atrial fibrillation, or persistent atrial fibrillation;
- Willing to provide clinical baseline data and allow access to CTA examination results;
- Able to understand and cooperate with the data collection process of the study.
Who cannot join
- Patients with incomplete clinical baseline data or unreadable CTA images;
- Aged less than 18 years
- Patients who refuse to participate in the study or cannot cooperate with data collection;
- Other situations judged by the researchers to be unsuitable for inclusion in the study.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Cardiac Computed Tomography Evaluation of Epicardial Adipose Tissue Differences Between Patients With Atrial Fibrillation and Non-Atrial Fibrillation Individuals
The goal of this cross-sectional study is to explore the relationship between atrial structural characteristics (such as epicardial adipose tissue infiltration and atrial size) and atrial fibrillation (AF), as well as the differences in these characteristics among different AF subtypes. It will also clarify the independent association between pericardial fat distribution and AF (and its subtypes) after excluding confounding factors.
The main questions it aims to answer are:
Read more
- What are the differences in epicardial adipose tissue volume and atrial size among patients with sinus rhythm, paroxysmal AF, and persistent AF?
- Is pericardial fat distribution independently associated with AF and its subtypes after adjusting for confounding factors such as age, hypertension, and left atrial enlargement?
Researchers will enroll patients who undergo coronary CTA or left atrial CTA at The Second Affiliated Hospital of Zhejiang University School of Medicine, and match and divide them into three groups (sinus rhythm group, paroxysmal AF group, and persistent AF group) based on BMI and other factors. They will compare the differences in pericardial fat distribution and baseline characteristics among the three groups and analyze the independent association between pericardial fat and AF.
Participants will:
- Provide relevant clinical baseline data and CTA examination results
- Complete the collection of demographic information, medical history, and laboratory test data
The study duration is 6 months, starting from the date of ethical approval, with an expected end date of June 2026. A total of 600-900 participants (200-300 per group) will be enrolled to ensure the reliability and clinical applicability of the research conclusions.
- Conditions
- Atrial Fibrillation (AF), CT
- Medical subject headings
- Atrial Fibrillation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Paroxysmal AF | Not described | |
| Persistent AF | Paroxysmal AF | |
| Sinus rhythm | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
The difference in epicardial adipose tissue distribution among the three cohorts
Measured: At the time of enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jan 2026
- Study start1 Jan 2026 (estimated)
- Primary completion28 Feb 2026 (estimated)
- Study completionAug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atrial Fibrillation (AF)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 600 participants (estimated)
Sponsor and investigators
- Lead sponsor
- xiaoya wang
- Sponsor type
- University, hospital or other
- Collaborators
- University of Auckland, New Zealand
- Responsible party
- Sponsor-investigator, xiaoya wang, Second Affiliated Hospital, Zhejiang University, School of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07320261
- Sponsor's protocol ID
- 2025-1638-1
- Acronym
- CCT-EAT-AF-NA
- Status last verified
- Dec 2025
- First submitted
- 22 Dec 2025
- Last updated
- 6 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: IPD will be shared with other researchers upon reasonable request. The shared data will include de-identified participant information relevant to the study objectives, such as demographic data, clinical baseline characteristics, CTA examination results, and statistical analysis datasets. To protect participant privacy, all shared data will be de-identified by removing personal identifiers (e.g., name, ID number, contact information) in accordance with ethical regulations and data protection policies of The Second Affiliated Hospital of Zhejiang University School of Medicine. Researchers requesting IPD must submit a research proposal demonstrating the scientific relevance of their study, agree to abide by data use agreements, and ensure that the shared data is only used for legitimate scientific research purposes.
Study at a glance
From the registry record, last updated by the sponsor on 6 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cardiac Computed Tomography Evaluation of Epicardial Adipose Tissue Differences Between Patients With Atrial Fibrillation and Non-Atrial Fibrillation Individuals
- ClinicalTrials.gov ID
- NCT07320261
- Acronym / sponsor ID
- CCT-EAT-AF-NA / 2025-1638-1
- Conditions
- Atrial Fibrillation (AF), CT
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 600 participants (estimated)
- Lead sponsor
- xiaoya wangUniversity, hospital or other
- Collaborators
- University of Auckland, New Zealand
- Study start
- 1 Jan 2026 (estimated)
- Primary completion
- 28 Feb 2026 (estimated)
- Study completion
- Aug 2026 (estimated)
- First posted
- 6 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this cross-sectional study is to explore the relationship between atrial structural characteristics (such as epicardial adipose tissue infiltration and atrial size) and atrial fibrillation (AF), as well as the differences in these characteristics among different AF subtypes. It will also clarify the independent association between pericardial fat distribution and AF (and its subtypes) after excluding confounding factors.
The main questions it aims to answer are:
- What are the differences in epicardial adipose tissue volume and atrial size among patients with sinus rhythm, paroxysmal AF, and persistent AF?
- Is pericardial fat distribution independently associated with AF and its subtypes after adjusting for confounding factors such as age, hypertension, and left atrial enlargement?
Researchers will enroll patients who undergo coronary CTA or left atrial CTA at The Second Affiliated Hospital of Zhejiang University School of Medicine, and match and divide them into three groups (sinus rhythm group, paroxysmal AF group, and persistent AF group) based on BMI and other factors. They will compare the differences in pericardial fat distribution and baseline characteristics among the three groups and analyze the independent association between pericardial fat and AF.
Participants will:
- Provide relevant clinical baseline data and CTA examination results
- Complete the collection of demographic information, medical history, and laboratory test data
The study duration is 6 months, starting from the date of ethical approval, with an expected end date of June 2026. A total of 600-900 participants (200-300 per group) will be enrolled to ensure the reliability and clinical applicability of the research conclusions.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Paroxysmal AF | – | – |
| Persistent AF | – | –Paroxysmal AF |
| Sinus rhythm | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The study population consists of adult patients aged 18 years or older who undergo coronary CTA or left atrial CTA examination at The Second Affiliated Hospital of Zhejiang University School of Medicine. Participants will be categorized into three cohorts according to their confirmed cardiac rhythm status: sinus rhythm, paroxysmal atrial fibrillation, or persistent atrial fibrillation. All enrolled individuals must be willing to provide clinical baseline data and allow access to their CTA examination results, and be able to understand and cooperate with the study's data collection process. Patients under 18 years of age, those with incomplete clinical data or unreadable CTA images, and those who refuse to participate or cannot cooperate will be excluded from the study. The total planned sample size is 600-900 participants, with 200-300 participants in each cohort.
Key inclusion criteria (5 listed)
- Patients who undergo coronary CTA or left atrial CTA examination at The Second Affiliated Hospital of Zhejiang University School of Medicine;
- Aged 18 years or older
- Cardiac rhythm status is confirmed as sinus rhythm, paroxysmal atrial fibrillation, or persistent atrial fibrillation;
- Willing to provide clinical baseline data and allow access to CTA examination results;
- Able to understand and cooperate with the data collection process of the study.
Key exclusion criteria (4 listed)
- Patients with incomplete clinical baseline data or unreadable CTA images;
- Aged less than 18 years
- Patients who refuse to participate in the study or cannot cooperate with data collection;
- Other situations judged by the researchers to be unsuitable for inclusion in the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The difference in epicardial adipose tissue distribution among the three cohorts
Time frame: At the time of enrollment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jan 2026.
- Individual participant dataSharing planned: Yes. IPD will be shared with other researchers upon reasonable request. The shared data will include de-identified participant information relevant to the study objectives, such as demographic data, clinical baseline characteristics, CTA examination results, and statistical analysis datasets. To protect participant privacy, all shared data will be de-identified by removing personal identifiers (e.g., name, ID number, contact information) in accordance with ethical regulations and data protection policies of The Second Affiliated Hospital of Zhejiang University School of Medicine. Researchers requesting IPD must submit a research proposal demonstrating the scientific relevance of their study, agree to abide by data use agreements, and ensure that the shared data is only used for legitimate scientific research purposes.
Related trials for Atrial Fibrillation (AF)
Active, not recruiting
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
Paroxysmal AF
Active, not recruiting
CONVERGE Post-Approval Study (PAS)
Chronic Atrial Fibrillation
RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Atrial Fibrillation (AF)
RecruitingPhase 3
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
Atrial Fibrillation (AF)
Not yet recruitingObservational study
Hummingbird ICE Study
ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATION, Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Atrial Fibrillation (AF) and CT, run by xiaoya wang.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xiaoya Wang, Doctor (86-0571-87784704, wxyonce@zju.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The difference in epicardial adipose tissue distribution among the three cohorts (time frame: At the time of enrollment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jan 2026.